Cost-Utility Analysis of Pitavastatin in Dyslipidemia: Vietnam Case

Abstract excerpt

<h4>Background: </h4> /Objectives: Dyslipidemia is becoming a significant economic healthcare burden in low- to middle-income countries (LMICs) due to its role in heightening cardiovascular-related mortality. Statins are the first-line treatment for reducing LDL-C levels, thereby minimizing direct costs associated with cardiovascular disease management, with pitavastatin being the newest generation of statins. Thi...

Topics

Open a Topic to create a Post that cites this publication.

• Acute Coronary Syndrome
• Clopidogrel
• Drug Costs
• Platelet Aggregation Inhibitors
• Quality-Adjusted Life Years
• Singapore
• Ticagrelor
• Ticlopidine

Identifiers and source

Literature Corpus work

ff8cb72a-ee98-5db8-9f31-8b477569ea83

DOI

10.20944/preprints202508.0661.v1